01 10Primaxin
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 250
2019 Revenue in Millions : 273
Growth (%) : -8
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 259
2020 Revenue in Millions : 250
Growth (%) : 4
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 239
2021 Revenue in Millions : 259
Growth (%) : -8
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2023 Revenue in Millions : 213
2022 Revenue in Millions : 239
Growth (%) : -11
Main Therapeutic Indication : Anti-bacterial
Currency : USD
2015 Revenue in Millions : 329
2014 Revenue in Millions : 313
Growth (%) : -5%
Main Therapeutic Indication : Anti-bacterial
Currency : USD
2014 Revenue in Millions : -1.80%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Anti-Bacterial
Currency : USD
2016 Revenue in Millions : 297
2015 Revenue in Millions : 313
Growth (%) : -5
Main Therapeutic Indication : Anti-bacterial
Currency : USD
2017 Revenue in Millions : 280
2016 Revenue in Millions : 297
Growth (%) : -6
Main Therapeutic Indication : Anti-Bacterial
Currency : USD
2018 Revenue in Millions : 265
2017 Revenue in Millions : 280
Growth (%) : -5%
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2019 Revenue in Millions : 273
2018 Revenue in Millions : 265
Growth (%) : 3
LOOKING FOR A SUPPLIER?
